Emoxypine Succinate (Mexidol) 125 mg – 60 Capsules

Emoxypine Succinate / Mexidol 125 mg — 60 oral research capsules. Emoxypine succinate (Mexidol) is the most extensively prescribed nootropic-antioxidant compound in the entire post-Soviet pharmaceutical market — the subject of more than 700 published clinical studies and routine clinical use in the Russian Federation and several CIS countries for cerebrovascular disease, vascular cognitive impairment, anxiety disorders and post-traumatic recovery. Pharmacologically, it pairs the structural antioxidant scaffold of emoxypine — a synthetic vitamin-B6 analogue of pyridoxine — with the mitochondrial substrate succinate, producing a hybrid molecule whose mechanism integrates membrane-stabilizing antioxidant activity with direct mitochondrial-respiratory-chain support.

Research Overview

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine) is a synthetic 3-hydroxypyridine derivative — structurally a vitamin-B6 (pyridoxine) analogue — developed at the Russian Academy of Medical Sciences in the 1960s as a membrane-stabilizing antioxidant [1]. Its succinate salt form (Mexidol) was introduced in the 1980s and combines the antioxidant activity of the emoxypine scaffold with the direct mitochondrial-substrate effects of succinic acid — a TCA-cycle intermediate that bypasses Complex I of the electron transport chain and donates electrons directly to Complex II, providing rescue capacity in conditions of Complex I dysfunction [1,2]. Mexidol is one of the most prescribed nootropic / cerebroprotective compounds in the entire post-Soviet pharmaceutical market, with more than 700 published clinical studies covering acute and chronic ischemic stroke, vascular cognitive impairment, dyscirculatory encephalopathy, generalized anxiety disorder, alcohol-withdrawal syndromes and traumatic brain injury [2,3]. Mechanisms of action documented in animal models include: direct lipid-peroxidation inhibition, GABA-A receptor positive allosteric modulation (the basis of the anxiolytic phenotype), mitochondrial-membrane stabilization, and benzodiazepine-receptor-independent anxiolysis with no measurable sedation, dependence or cognitive impairment.

Primary Research Areas

• Cerebrovascular and ischemic-stroke research — the principal Russian-clinical-literature indication; investigated in acute and chronic cerebral ischemia models with reproducible neuroprotective signals [1,2].
• Mitochondrial bioenergetics — the succinate moiety provides Complex-II-direct electron donation, with rescue capacity in Complex-I-deficient mitochondrial models [2].
• Anxiolytic pharmacology — GABA-A positive allosteric modulation produces anxiolysis without the sedation, dependence or cognitive impairment of classical benzodiazepines [3].
• Vascular cognitive impairment — the principal contemporary clinical-research indication in CIS countries; investigated in dyscirculatory encephalopathy and post-stroke cognitive recovery [2].
• Antioxidant and membrane-stabilization research — documented direct lipid-peroxidation inhibition and mitochondrial-membrane-stabilization activity at physiological concentrations [1].

References

1. Voronina TA. Mexidol: spectrum of pharmacological activity. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(12):86–90.
2. Skvortsova VI, Stakhovskaya LV, Nartsissov YR, et al. A randomized, double-blind, placebo-controlled study of mexidol use in ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;Suppl 18:47–54.
3. Voronina TA, Yarkova MA, Belyy VP. Anxiolytic activity of the new pyridine derivative mexidol. Eksp Klin Farmakol. 2013;76(7):3–6.